Anticonvulsant agents

Pharmacokinetics in Drug Discovery and Development

Volumn , Issue , 2002, Pages 231-264

  Anderson, Gail D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953538327     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (71)

1. Beghi, E. and Perucca, E., The management of epilepsy in the 1990‘s, Drugs, 49: 680-694, 1995.
2. Morselli, P. L., Carbamazepine: absorption, distribution and excretion, in Antiepileptic Drugs, 4th ed., Levy, R.H., Mattson, R. H., and Meldrum, B. S., Eds., Raven Press, New York, 1995, 515-528.
3. Thomson, A. H. and Brodie, M. J., Pharmacokinetic optimisation of anticonvulsant therapy, Clin. Pharmacokinet., 23: 216-230, 1992.
4. Bertilsson, L. and Tomson, T., Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11 epoxide, an update, Clin. Pharmacokinet., 11: 177-198, 1986.
5. Mattson, R. H. et al., Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures, N. Engl. J. Med., 313: 145-151, 1985.
6. Loiseau, P. and Duche, B., Carbamazepine: clinical use, in Antiepileptic Drugs, 4th ed., Levy, R. H., Mattson, R. H., and Meldrum, B. S., Eds., Raven Press, New York, 1994, 555-566.
7. Cheshire, W. P., Trigeminial neuralgia: a guide to drug choice, CNS Drugs, 7: 98-110, 1997.
8. Albani, F., Riva, R., and Baruzzi, A., Carbamazepine clinical pharmacology: a review, Pharmacopsychiatry, 28: 235-244, 1995.
9. Bell, W. L., Crawford, I. L., and Shiu, G.K., Reduced bioavailability of moistureexposed carbamazepine resulting in status epilepticus, Epilepsia, 34: 1102-1104, 1993.
10. Nuwer, M. et al., Generic substitution for antiepileptic drugs, Neurology, 40: 1647-1651, 1990.
11. Kerr, B. M. et al., Human liver carbamazepine: role of CYP3A4 and CYP2A8 in 10,11 epoxide formation, Biochem. Pharmacol., 47: 1769-1779, 1994.
12. Kerr, B. M. and Levy, R. H., Carbamazepine: carbamazepine epoxide, in Antiepileptic Drugs, 4th ed., Levy, R. H., Mattson, R. H., and Meldrum, B. S., Eds., Raven Press, New York, 1995, 529-541.
13. Anderson, G., A mechanistic approach to antiepileptic drug interactions, Ann. Pharmacother., 32: 554-563, 1998.
14. Battino, D., Estienne, M., and Avanzini, G., Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate, Clin. Pharmacokinet., 29: 341-369, 1995.
15. Willmore, L. J., Antiepileptic drug therapy in the elderly, Pharmacol. Ther., 78: 9-16, 1998.
16. Faught, E., Epidemiology and drug treatment of epilepsy in elderly people, Drugs Aging, 15: 255-269, 1999.
17. Lander, C. M and Eadie, M. J., Plasma antiepileptic drug concentrations during pregnancy, Epilepsia, 32: 257-266, 1991.
18. Hagg, S. and Spigset, O., Anticonvulsant use during lactation, Drug Saf., 22: 425-440, 2000.
19. Pisani, F. and Bialer, M., Ethosuximide: absorption, distribution and excretion, in Antiepileptic Drugs, 4th ed., Levy, R. H., Mattson, R. H., and Meldrum, B. S., Eds., Raven Press, New York, 1994.
20. Morselli, P. L. and Fracno-Morselli, R., Clinical pharmacokinetics of antiepileptic drugs in adults. Pharmacol. Ther., 10: 65-101, 1980.
21. Sherwin, A. L., Ethosuximide: Clinical use, in Antiepileptic Drugs, 4th ed., Levy, R. H., Mattson, R. H., and Meldrum, B. S., Eds., Raven Press, New York, 1994.
22. Battino, D., Estienne, M., and Avanzini, G., Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide, Clin. Pharmacokinet., 29: 257-286, 1995.
23. Palmer, K. and McTavish, D., Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy, Drugs, 45: 1041-1065, 1993.
24. Graves, N. M., Felbamate, Ann. Pharmacother., 27: 1073-1081, 1993.
25. Walker, M. C. and Patsalos, P. N., Clinical pharmacokinetics of new antiepileptic drugs, Pharmacol. Ther., 3: 351-384, 1995.
26. Glue, P. et al., Pharmacokinetic interactions with felbamate: in vitro-in vivo correlation, Clin. Pharmacokinet., 33: 214-224, 1997.
27. Andrews, C. O. and Fischer, J. H., Gabapentin: a new agent for the management of epilepsy, Ann. Pharmacother., 28: 1188-1196, 1994.
28. Gidal, B. E. et al., Inter-and intra-subject variability in gabapentin absorption and absolute bioavailability, Epilepsy Res., 40: 123-127, 2000.
29. Blum, R. A. et al., Pharmacokinetics of gabapentin in subjects with various degrees of renal function, Clin. Pharmacol. Ther., 56: 154-159, 1994.
30. Goa, K. L., Ross, S. R., and Chrisp, P., Lamotrigine, a review of its pharmacological properties and clinical efficacy in epilepsy, Drugs, 46: 152-176, 1993.
31. Green, M. D., Bishop, W. P., and Tephley, T. R., Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides, Drug Metab. Dispos., 23: 299-302, 1995.
32. Posner, J., Holdich, T., and Crome, P., Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers, J. Pharm. Med., 1: 121-128, 1991.
33. Tomson, T., Ohman, I., and Vitols, S., Lamotrigine in pregnancy and lactation: a case report, Epilepsia, 38: 1039-1041, 1997.
34. Patsalos, P. N., Pharmacokinetic profile of levetiracetam: toward ideal characteristics, Pharmacol. Ther., 85: 77-85, 2000.
35. Benedetti, M. S., Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies, Fundam. Clin. Pharmacol., 14: 301-319, 2000.
36. Nicolas, J.-M. et al., In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent, Drug Metab. Dispos., 27: 250-254, 1999.
37. Lott, R. S. and Helmboldt, K., Oxcarbazepine: a carbamazepine analogue for partial seizures in adults and children with epilepsy, Formulary, 35: 1-9, 2000.
38. van Heiningen, P. N. et al., The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine, Clin. Pharmacol. Ther., 50: 410-419, 1991.
39. Rouan, M. C. et al, The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites, Eur. J. Clin. Pharmacol., 47: 161-167, 1994.
40. Dodson, W. E. and Rust, R. S., Phenobarbital: absorption, distribution and excretion, in Antiepileptic Drugs, 4th ed., Levy, R. H., Mattson, R. H., and Meldrum, B. S., Eds., Raven Press, New York, 1994.
41. Nelson, E. et al., Phenobarbital pharmacokinetics and bioavailability in adults, J. Clin. Pharmacol., 22: 141-148, 1982.
42. Wilensky, A. J. et al. Kinetics of phenobarbital in normal subjects and epileptic patients, Eur. J. Clin. Pharmacol., 23: 87-92, 1982.
43. Hargraves, J. A. et al., Identification of enzymes responsible for the metabolism of phenobarbital (abstract), Int. Soc. Stud. Xenobiotics Proc., 10: 259, 1996.
44. Nau, H. et al., Placental transfer and pharmacokinetics of primidone and its metabolites, phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers, Eur. J. Clin. Pharmacol., 18: 18-42, 1980.
45. Treiman, D. M. and Woodbury, D. M., Phenytoin: absorption, distribution and excretion, in Antiepileptic Drugs, 4th ed., Levy, R. H., Mattson, R. H., and Meldrum, B. S., Eds., Raven Press, New York, 1995, 301-314.
46. Richens, A., Clinical pharmacokinetics of phenytoin, Clin. Pharmacokinet., 4: 153-169, 1979.
47. Jung, D. et al., Effect of dose on phenytoin absorption, Clin. Pharmacol. Ther., 28(4): 479-485, 1980.
48. Bajpai, M. et al., Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolites, Drug Metab. Dispos., 24: 1401-1403, 1996.
49. Graves, N. M. et al., Phenytoin clearances in a compliant population: description and application, Ther. Drug Monit., 8: 427-433, 1986.
50. Privitera, M. D., Clinical rules for phenytoin dosing, Ann. Pharmacother., 27: 1169-1173, 1993.
51. Ludden, T. M. et al., Individualization of phenytoin dosage regimens, Clin. Pharmacol. Ther., 21: 287-293, 1977.
52. Levine, M. and Chang, T., Therapeutic drug monitoring of phenytoin. Rationale and current status, Clin. Pharmacokinet., 19: 341-358, 1990.
53. Anderson, G. D. et al., Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia, Ann. Pharmacother., 31: 279-284, 1997.
54. Haidukewych, D., Rodin, E. A., and Zielinski, J. J., Derivation and evaluation of an equation for prediction of free phenytoin concentrations in patients co-medicated with valproic acid, Ther. Drug Monit., 11: 134-139, 1989.
55. Bachmann, K. A. and Belloto, R. J. J., Differential kinetics of phenytoin in elderly patients, Drugs Aging, 15: 235-250, 1999.
56. Cloyd, J. C., and Leppik, I. E., Primidone: absorption, distribution and excretion, in Antiepileptic Drugs, 4th ed., Levy, R. H., Mattson, R. H., and Meldrum B. S., Eds., Raven Press, New York, 1994, 459-466.
57. Martines, C. et al., The disposition of primidone in elderly patients, Br. J. Clin. Pharmacol., 30: 607-611, 1990.
58. Perucca, E. and Bialer, M., The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine, Clin. Pharmacokinet., 31: 29-41, 1996.
59. Luer, M. S. and Rhoney, D. H., Tiagabine: a novel antiepileptic drug, Ann. Pharmacother., 32: 1173-1180, 1998.
60. Jansen, S. S. et al., The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy, J. Clin. Pharmacol., 37: 1015-1020, 1997.
61. Cato, Ar. et al., Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine, Epilepsia, 39: 43-47, 1998.
62. Privitera, M. D., Topiramate: a new antiepileptic drug, Ann. Pharmacother., 31: 1164-1173, 1997.
63. Sachdeo, R. C., Topiramate: clinical profile in epilepsy, Clin. Pharmacokinet., 34: 335-346, 1998.
64. Rosenfeld, W. E. et al., A study of topiramate pharmacokinetics and tolerability in children with epilepsy, Pediatr. Neurol., 20: 339-344, 1999.
65. Glauser, T. A. et al., Topiramate pharmacokinetics in infants, Epilepsia, 40: 788-791, 1999.
66. Levy, R. H. and Shen, D. D., Valproic acid: absorption, distribution, and excretion, in Antiepileptic Drugs, 4th ed., Levy, R. H., Mattson, R. H. and Meldrum, B. S., Eds., Raven Press, New York, 1995, 605-619.
67. Levy, R. H., Variability in level-dose ratio of valproate: monotherapy versus polytherapy, Epilepsia, 25 (Suppl. 1): S10-S13, 1984.
68. Cloyd, J. C. et al., Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy, Neurology, 33: 185-191, 1983.
69. Bauer, L. A. et al., Valpric acid clearance: unbound fraction and dirunal variations in young and elderly adults, Clin. Pharmacol. Ther., 37: 697-700, 1985.
70. Klotz, U., Rapp, T., and Muller, W. A., Disposition of valproic acid in patients with liver disease, Eur. J. Clin. Pharmacol., 13: 55-60, 1978.
71. Peters, D. H. and Sorkin, E. M., Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy, Drugs, 45: 760-787, 1993.